Per- and polyfluoroalkyl substances and cardiometabolic diseases: A review

dc.contributor.authorSchillemans, Tessa
dc.contributor.authorDonat Vargas, Carolina
dc.contributor.authorÅkesson, Agneta
dc.date.accessioned2026-09-23T09:09:18Z
dc.date.available2026-09-23T09:09:18Z
dc.date.issued2023-10-22
dc.date.updated2026-09-23T09:09:18Z
dc.description.abstractPer- and polyfluoroalkyl substances (PFAS) are a group of persistent and widespread environmental pollutants that represent a high concern for human health. They have been shown to be associated with several important physiological processes such as lipid metabolism and the immune system. Consequently, PFAS are suspected to play a role in cardiometabolic disease development. However, the evidence regarding associations between PFAS and overt cardiovascular disease and type 2 diabetes remains limited and inconsistent. To address this, we conducted a review of the epidemiological evidence. A deeper understanding of potential underlying molecular mechanisms may help to explain inconsistencies in epidemiological findings. Thus, to gain more mechanistic insight, we also summarized evidence from omics and laboratory studies into an adverse outcome pathway framework. Our observations indicate the potential for associations of PFAS with multiple molecular pathways that could have opposite associations with disease risk, which could be further modified by mixture composition, lifestyle factors or genetic polymorphisms. This identifies the need for exposome studies considering mixture effects, the use of multi-omics data to gain insight in relevant pathways and the integration of epidemiological and laboratory studies to enhance mechanistic understanding and causal inference. Improved comprehension is essential for environmental health risk assessments.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec771936
dc.identifier.issn1742-7835
dc.identifier.pmid37817473
dc.identifier.urihttps://hdl.handle.net/2445/231638
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/bcpt.13949
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicology, 2023, vol. 134, num.1, p. 141-152
dc.relation.urihttps://doi.org/10.1111/bcpt.13949
dc.rightscc by-nc (c) Tessa Schillemans, et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationMetabolisme
dc.subject.classificationContaminants
dc.subject.otherCardiovascular diseases
dc.subject.otherMetabolism
dc.subject.otherPollutants
dc.titlePer- and polyfluoroalkyl substances and cardiometabolic diseases: A review
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
943356.pdf
Mida:
495.92 KB
Format:
Adobe Portable Document Format